Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer

被引：0
|
作者：
Feyerabend, S. [1 ]
Saad, F. [2 ]
Li, T. [3 ]
Ito, T. [4 ]
Diels, J. [5 ]
Van Sanden, S. [5 ]
De Porre, P. [6 ]
Roiz, J. [7 ]
Abogunrin, S. [8 ]
Fizazi, K. [9 ]
机构：
[1] Studienpraxis Urol, Urol Oncol, Nurtingen, Germany
[2] CRCHUM, Ctr Hosp Univ Montreal, Surg, Montreal, PQ, Canada
[3] Janssen Global Serv, Global Market Access Oncol, Raritan, NJ USA
[4] Janssen, Hlth Econ & Market Access EMEA, High Wycombe, Bucks, England
[5] Janssen, Hlth Econ & Market Access EMEA, Beerse, Belgium
[6] Janssen Res & Dev BE, Clin Oncol, Beerse, Belgium
[7] Modeling & Simulat, London, England
[8] Evidera, Outcomes Res, London, England
[9] Univ Paris Sud, Inst Gustave Roussy, Canc Med, Villejuif, France
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
803P
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Comment on Real-world Efficacy and Toxicity Analysis of Abiraterone Acetate versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer in Asian Patients
    Sudhakaran, Gokul
    CLINICAL GENITOURINARY CANCER, 2024, 22 (05)
  • [22] Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice
    Lendorf, Maria Elisabeth
    Petersen, Peter Meidahl
    Svendsen, Andrea Steen
    Lindberg, Henriette
    Brasso, Klaus
    EUROPEAN UROLOGY OPEN SCIENCE, 2021, 24 : 25 - 33
  • [23] Modern treatment of metastatic hormone-sensitive prostate cancer
    Kuronya Zsofia
    Biro Krisztina
    Geczi Lajos
    Maraz Aniko
    ORVOSI HETILAP, 2018, 159 (41) : 1664 - 1671
  • [24] Optimal treatment for metastatic hormone-sensitive prostate cancer
    Omlin, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 18 - 19
  • [25] Advancements in the treatment of metastatic hormone-sensitive prostate cancer
    Li, Hengping
    Zhang, Mao
    Wang, Xiangrong
    Liu, Yang
    Li, Xuanpeng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Treatment options for metastatic hormone-sensitive prostate cancer
    Kostos, Louise
    Murphy, Declan G.
    LANCET ONCOLOGY, 2022, 23 (10): : 1234 - 1235
  • [27] The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation
    McNamara, Megan
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Armstrong, Andrew J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (03) : 306 - 318
  • [28] The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation
    Megan McNamara
    Christopher Sweeney
    Emmanuel S. Antonarakis
    Andrew J. Armstrong
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 306 - 318
  • [29] Treatment of primary cancer in metastatic hormone-sensitive prostate cancer
    Lim, Kylie Y. -Y.
    Alberto, Matthew
    Ranasinghe, Weranja
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2023, 17 (04) : 315 - 323
  • [30] Metastatic hormone-sensitive prostate cancer
    Gravis, Gwenaelle
    Salem, Naji
    Walz, Jochen
    BULLETIN DU CANCER, 2015, 102 (01) : 57 - 64
12345